Mahajan Imaging and Labs, a prominent diagnostic center chain in India, has unveiled an Artificial Intelligence-integrated blood biomarker test, complemented by structured PET and MRI imaging pathways, to facilitate the early detection of Alzheimer's disease. Launched on January 19, 2026, this innovative diagnostic approach aims to revolutionize Alzheimer's care in Indian clinical practice by shifting from symptom-led assessments to a 'biology-first diagnosis'. The core of this new method is the pTAU/Aβ1-42 blood biomarker test, which has received approval from both the US Food and Drug Administration (USFDA) and India's Central Drugs Standard Control Organisation (CDSCO). This approval underscores the test's credibility and its adherence to international and national regulatory standards. The blood test is designed to identify Alzheimer's-related biological changes long before severe cognitive symptoms manifest, offering a crucial window for earlier intervention and care planning. This is particularly significant given that over 8.8 million Indians aged 60 and above currently live with dementia, a number projected to almost double in the next decade, highlighting the urgent need for advanced diagnostic tools. Experts at the launch symposium in Gurugram emphasized that integrating AI-driven blood biomarkers with advanced imaging represents a transformative step for Indian neurology. This combined approach provides a less invasive and more affordable alternative to traditional diagnostic methods like cerebrospinal fluid (CSF) testing or expensive amyloid PET imaging, which have limited accessibility and high costs in India. The ability to obtain critical diagnostic information through a simple blood test makes the process easier, safer, and more acceptable for patients, aligning Indian diagnostics with evolving global standards in Alzheimer's care.